RU2009107030A - Комбинированная терапия - Google Patents
Комбинированная терапия Download PDFInfo
- Publication number
- RU2009107030A RU2009107030A RU2009107030/15A RU2009107030A RU2009107030A RU 2009107030 A RU2009107030 A RU 2009107030A RU 2009107030/15 A RU2009107030/15 A RU 2009107030/15A RU 2009107030 A RU2009107030 A RU 2009107030A RU 2009107030 A RU2009107030 A RU 2009107030A
- Authority
- RU
- Russia
- Prior art keywords
- inhibitor
- pharmaceutically acceptable
- acceptable salt
- vla
- use according
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 claims abstract 32
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims abstract 18
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims abstract 18
- 150000003839 salts Chemical class 0.000 claims abstract 17
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims abstract 14
- 238000000034 method Methods 0.000 claims abstract 10
- MNQBPRHHZPXCKZ-ZDCRTTOTSA-N (2s)-2-[[(2s)-1-(3,5-dichlorophenyl)sulfonylpyrrolidine-2-carbonyl]amino]-4-[[(2s)-4-methyl-2-[methyl-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]pentanoyl]amino]butanoic acid Chemical group CN([C@@H](CC(C)C)C(=O)NCC[C@H](NC(=O)[C@H]1N(CCC1)S(=O)(=O)C=1C=C(Cl)C=C(Cl)C=1)C(O)=O)C(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C MNQBPRHHZPXCKZ-ZDCRTTOTSA-N 0.000 claims abstract 7
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical group C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 claims abstract 7
- 229960002169 plerixafor Drugs 0.000 claims abstract 7
- 210000004027 cell Anatomy 0.000 claims abstract 6
- 201000010099 disease Diseases 0.000 claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- 230000003211 malignant effect Effects 0.000 claims abstract 4
- 210000005259 peripheral blood Anatomy 0.000 claims abstract 4
- 239000011886 peripheral blood Substances 0.000 claims abstract 4
- 210000000130 stem cell Anatomy 0.000 claims abstract 4
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims abstract 3
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims abstract 3
- 206010025323 Lymphomas Diseases 0.000 claims abstract 3
- 239000000556 agonist Substances 0.000 claims abstract 3
- 238000002617 apheresis Methods 0.000 claims abstract 2
- 238000002512 chemotherapy Methods 0.000 claims abstract 2
- 238000012258 culturing Methods 0.000 claims abstract 2
- 230000003394 haemopoietic effect Effects 0.000 claims abstract 2
- 208000032839 leukemia Diseases 0.000 claims abstract 2
- 230000001483 mobilizing effect Effects 0.000 claims abstract 2
- 238000001959 radiotherapy Methods 0.000 claims abstract 2
- CWJJHESJXJQCJA-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine Chemical group C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CNCC1=CC=CC=N1 CWJJHESJXJQCJA-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 claims 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83529006P | 2006-08-02 | 2006-08-02 | |
| US60/835,290 | 2006-08-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009107030A true RU2009107030A (ru) | 2010-09-10 |
Family
ID=38997866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009107030/15A RU2009107030A (ru) | 2006-08-02 | 2007-08-02 | Комбинированная терапия |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100003224A1 (https=) |
| EP (1) | EP2068868A2 (https=) |
| JP (1) | JP2009545620A (https=) |
| CN (1) | CN101495115A (https=) |
| AR (1) | AR063470A1 (https=) |
| AU (1) | AU2007281090A1 (https=) |
| BR (1) | BRPI0714799A2 (https=) |
| CA (1) | CA2659463A1 (https=) |
| IL (1) | IL196556A0 (https=) |
| MX (1) | MX2009001272A (https=) |
| RU (1) | RU2009107030A (https=) |
| WO (1) | WO2008017025A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003261723A1 (en) | 2002-08-27 | 2004-03-19 | Takeda Chemical Industries, Ltd. | Cxcr4 antagonist and use thereof |
| WO2008075371A2 (en) | 2006-12-21 | 2008-06-26 | Biokine Therapeutics Ltd. | T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation |
| BRPI1009663A2 (pt) | 2009-06-14 | 2016-10-11 | Biokine Therapeutics Ltd | "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica" |
| JP2013541520A (ja) * | 2010-09-17 | 2013-11-14 | アンチセンス・セラピューティックス・リミテッド | 幹細胞および／または前駆細胞を動員するための方法 |
| WO2012129073A2 (en) * | 2011-03-18 | 2012-09-27 | University Of Virginia Patent Foundation | Compositions and methods for tissue engineering and cell based therapies |
| KR20140045411A (ko) | 2011-05-16 | 2014-04-16 | 젠자임 코포레이션 | Ｃｘｃｒ４ 길항제의 용도 |
| EP2720690A4 (en) * | 2011-06-16 | 2014-12-31 | Childrens Medical Center | COMBINED CHEMICAL MODIFICATION OF SPHINGOSIN-1-PHOSPHATE (S1P) AND CXCR4 SIGNALING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND TRANSPLANT |
| EP2841084B1 (en) | 2012-04-24 | 2018-05-30 | Biokine Therapeutics Ltd. | Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer |
| CA2970114A1 (en) * | 2014-12-12 | 2016-06-16 | Commonwealth Scientific And Industrial Research Organisation | Dislodgement and release of hsc using alpha 9 integrin antagonist and cxcr4 antagonist |
| US10786547B2 (en) | 2015-07-16 | 2020-09-29 | Biokine Therapeutics Ltd. | Compositions, articles of manufacture and methods for treating cancer |
| KR102033920B1 (ko) | 2016-02-23 | 2019-10-18 | 바이오라인알엑스 리미티드 | 급성 골수성 백혈병을 치료하는 방법 |
| WO2017177167A1 (en) * | 2016-04-08 | 2017-10-12 | Syros Pharmaceuticals, Inc. | Rara agonists for the treatment of aml and mds |
| WO2018085574A2 (en) * | 2016-11-02 | 2018-05-11 | Washington University | Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof |
| TWI734027B (zh) * | 2017-09-18 | 2021-07-21 | 泰宗生物科技股份有限公司 | 用於治療癌症之組合物 |
| CN111712262A (zh) * | 2017-12-06 | 2020-09-25 | 美真达治疗公司 | 用于动员造血干细胞和祖细胞的给药方案 |
| US11260079B2 (en) | 2017-12-06 | 2022-03-01 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001826A (en) * | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
| US5021409A (en) * | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| GB9126677D0 (en) * | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| US6447766B1 (en) * | 1993-06-08 | 2002-09-10 | Smithkline Beecham Corporation | Method of mobilizing hematopoietic stem cells |
| ES2210255T3 (es) * | 1993-06-08 | 2004-07-01 | Smithkline Beecham Corporation | Metodos para mejorar la actividad biologica de quimiocinas. |
| US5510332A (en) * | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
| CN1081685C (zh) * | 1994-08-19 | 2002-03-27 | 阿克佐诺贝尔公司 | 纤维素溶液及其制得的产品 |
| US6506770B1 (en) * | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| US5968546A (en) * | 1997-05-16 | 1999-10-19 | Baur; Marcus | Keratinocyte culture from precursor cells |
| NZ509199A (en) * | 1998-05-28 | 2003-10-31 | Biogen Inc | A VLA-4 inhibitor: oMePUPA-V |
| US6365583B1 (en) * | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
| US6750348B1 (en) * | 1999-03-24 | 2004-06-15 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| CZ2002518A3 (cs) * | 1999-08-13 | 2002-05-15 | Biogen, Inc. | Inhibitory buněčné adheze a farmaceutické prostředky, které je obsahují |
| AU2334301A (en) * | 1999-12-17 | 2001-06-25 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
| US6734191B2 (en) * | 2000-09-15 | 2004-05-11 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| HK1052011A1 (zh) * | 2000-09-15 | 2003-08-29 | Anormed Inc. | 趋化因子受体结合杂环化合物 |
| DE60137435D1 (de) * | 2000-09-15 | 2009-03-05 | Anormed Inc | Chemokin rezeptor bindenden heterozyklische verbindungen |
| DE60136476D1 (de) * | 2000-09-29 | 2008-12-18 | Anormed Inc | -stickstoffhaltigen zyklischen polyaminen und deren verbindungen |
| WO2004091518A2 (en) * | 2003-04-11 | 2004-10-28 | Anormed Inc. | Cxcr4 chemokine receptor binding compounds |
| US7501518B2 (en) * | 2003-04-22 | 2009-03-10 | Genzyme Corporation | Methods of making 2,6-diaryl piperidine derivatives |
| JP4778420B2 (ja) * | 2003-04-22 | 2011-09-21 | アノーメッド インコーポレイティド | 増強された有効性を有するケモカインレセプタ結合複素環式化合物 |
| EP1708703A4 (en) * | 2003-12-11 | 2008-04-09 | Anormed Inc | CHEMOKIN RECEPTOR BINDING COMPOUNDS |
| EP1730113B1 (en) * | 2004-03-15 | 2016-12-28 | Genzyme Corporation | Process for the synthesis of a cxcr4 antagonist |
| JP2008509928A (ja) * | 2004-08-13 | 2008-04-03 | アノーメド インコーポレイテッド | 前駆／幹細胞を動員するためのケモカインの組み合わせ |
| US7825088B2 (en) * | 2005-04-25 | 2010-11-02 | The Cbr Institute For Biomedical Research, Inc. | Methods for the treatment of multiple myeloma |
-
2007
- 2007-08-02 US US12/375,987 patent/US20100003224A1/en not_active Abandoned
- 2007-08-02 AR ARP070103423A patent/AR063470A1/es not_active Application Discontinuation
- 2007-08-02 CA CA002659463A patent/CA2659463A1/en not_active Abandoned
- 2007-08-02 BR BRPI0714799-6A patent/BRPI0714799A2/pt not_active Application Discontinuation
- 2007-08-02 MX MX2009001272A patent/MX2009001272A/es unknown
- 2007-08-02 RU RU2009107030/15A patent/RU2009107030A/ru not_active Application Discontinuation
- 2007-08-02 WO PCT/US2007/075064 patent/WO2008017025A2/en not_active Ceased
- 2007-08-02 CN CNA200780028588XA patent/CN101495115A/zh active Pending
- 2007-08-02 AU AU2007281090A patent/AU2007281090A1/en not_active Abandoned
- 2007-08-02 JP JP2009523051A patent/JP2009545620A/ja not_active Withdrawn
- 2007-08-02 EP EP07813695A patent/EP2068868A2/en not_active Withdrawn
-
2009
- 2009-01-15 IL IL196556A patent/IL196556A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007281090A1 (en) | 2008-02-07 |
| WO2008017025A3 (en) | 2008-10-09 |
| EP2068868A2 (en) | 2009-06-17 |
| BRPI0714799A2 (pt) | 2013-05-21 |
| CA2659463A1 (en) | 2008-02-07 |
| US20100003224A1 (en) | 2010-01-07 |
| MX2009001272A (es) | 2009-02-11 |
| IL196556A0 (en) | 2009-11-18 |
| CN101495115A (zh) | 2009-07-29 |
| JP2009545620A (ja) | 2009-12-24 |
| AR063470A1 (es) | 2009-01-28 |
| WO2008017025A2 (en) | 2008-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009107030A (ru) | Комбинированная терапия | |
| RU2009108289A (ru) | Комбинированная терапия | |
| JP2009545620A5 (https=) | ||
| Pusic et al. | Update on clinical experience with AMD3100, an SDF-1/CXCL12–CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells | |
| Fruehauf et al. | It's moving day: factors affecting peripheral blood stem mobilization and strategies for improvement. | |
| US8685728B2 (en) | Kit containing stem cells and cytokines for use in attenuating immune responses | |
| Liesveld et al. | Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells | |
| ES2756336T3 (es) | Métodos que modulan el efecto inmunorregulador de las células madre | |
| Mohty et al. | In and out of the niche: perspectives in mobilization of hematopoietic stem cells | |
| Shao et al. | Transplantation of bone marrow–derived mesenchymal stem cells after regional hepatic irradiation ameliorates thioacetamide-induced liver fibrosis in rats | |
| JP2023085370A5 (https=) | ||
| AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
| CA2560058A1 (en) | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis | |
| EP3064220A3 (en) | Compositions and methods for the treatment of infections and tumors | |
| RU2009100930A (ru) | Лекарственные средства для стимуляции роста гемопоэтических стволовых клеток | |
| CO6311007A2 (es) | Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+, efectiva a dosis bajas | |
| NZ578928A (en) | Methods to increase mobility of hematopoietic stem cells by use of a lipopeptide compound and treatment of associated diseases | |
| Marquez-Curtis et al. | The ins and outs of hematopoietic stem cells: studies to improve transplantation outcomes | |
| Milling et al. | Neoadjuvant STING activation, extended half-life IL2, and checkpoint blockade promote metastasis clearance via sustained NK-cell activation | |
| CN105934155A (zh) | 在调节疼痛和/或纤维化中使用脂肪组织来源的细胞的方法 | |
| EA200500757A1 (ru) | Новое применение декстрансульфата | |
| Leung et al. | Haematopoietic stem cell transplantation: current concepts and novel therapeutic strategies | |
| Jin et al. | Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma | |
| Wesson et al. | Stem cells in acute liver failure | |
| Hildebrandt et al. | SDF-1 (CXCL12) in haematopoiesis and leukaemia: impact of DPP IV/CD26 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20100803 |